Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 1c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.27), $0.01 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $254 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Restoration Hardware (RH) PT Raised to $130 at Stifel After Q1 Earnings
• RH (RH) Tops Q1 EPS by 12c